Literature DB >> 14967189

The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia.

Kuei-Ru Chou1, Ruey Chen, Jia-Fu Lee, Chih-Hung Ku, Ru-Band Lu.   

Abstract

The purpose of this study was to determine the effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. This was a longitudinal study and sixty-eight schizophrenic patients were assigned to 8 weeks of a nicotine-patch therapy program or a control group. The generalized estimating equation analysis revealed that there were significant reductions in the subjects' nicotine dependence (Fagerstrom Tolerance Questionnaire), the number of cigarettes per day, and CO levels over an 8-week period of nicotine-patch therapy and 3-month follow-up. The point-prevalence rates of abstinence from smoking were an abstinence of 26.9% at 8 weeks and 26.9% at a 3-month follow-up. At the 3-month follow-up, the rate of continuous smoking abstinence in the nicotine-patch group was 23.1%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967189     DOI: 10.1016/j.ijnurstu.2003.07.001

Source DB:  PubMed          Journal:  Int J Nurs Stud        ISSN: 0020-7489            Impact factor:   5.837


  16 in total

1.  A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients.

Authors:  Hsing-Kang Chen; Tsuo-Hung Lan; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-23       Impact factor: 5.270

2.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

3.  Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia.

Authors:  Christopher G AhnAllen; Paul G Nestor; Martha E Shenton; Robert W McCarley; Margaret A Niznikiewicz
Journal:  Schizophr Res       Date:  2007-09-19       Impact factor: 4.939

4.  A smoking ban in psychiatric units: threat or opportunity?

Authors:  Lindsay Banham; Simon Gilbody; Helen Lester
Journal:  Ment Health Fam Med       Date:  2008-09

Review 5.  Treatment of tobacco dependence in people with mental health and addictive disorders.

Authors:  Kristen M Mackowick; Marie-Josee Lynch; Andrea H Weinberger; Tony P George
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

Review 6.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.

Authors:  Tony P George; Jennifer C Vessicchio; Kristi A Sacco; Andrea H Weinberger; Melissa M Dudas; Taryn M Allen; Cerissa L Creeden; Marc N Potenza; Alan Feingold; Peter I Jatlow
Journal:  Biol Psychiatry       Date:  2007-12-21       Impact factor: 13.382

8.  Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia.

Authors:  Kuan-Ju Chou; Hsing-Kang Chen; Chih-Hung Hung; Tzu-Ting Chen; Chun-Ming Chen; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-07-09       Impact factor: 5.270

9.  Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.

Authors:  Sarah C Akerman; Mary F Brunette; Douglas L Noordsy; Alan I Green
Journal:  Curr Addict Rep       Date:  2014-09-27

10.  Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis.

Authors:  Edward J Mills; Ping Wu; Dean Spurden; Jon O Ebbert; Kumanan Wilson
Journal:  Harm Reduct J       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.